CK Life Sciences Intl (Holdings) Inc
HKEX:775

Watchlist Manager
CK Life Sciences Intl (Holdings) Inc Logo
CK Life Sciences Intl (Holdings) Inc
HKEX:775
Watchlist
Price: 0.84 HKD Market Closed
Market Cap: 8.1B HKD

EV/EBITDA
Enterprise Value to EBITDA

222.7
Current
23.8
Median
6.4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
222.7
=
Enterprise Value
12.6B HKD
/
EBITDA
56.4m HKD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
HK
CK Life Sciences Intl (Holdings) Inc
HKEX:775
Average EV/EBITDA: 59.8
222.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.7
839%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A